Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients

Abstract

// Litao Xu 1, 2, * , Shulin Yu 1, 2, * , Liping Zhuang 1, 2, * , Peng Wang 1, 2 , Yehua Shen 1, 2 , Junhua Lin 1, 2 , Zhiqiang Meng 1, 2 1 Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China * These authors contributed equally to this work and should be considered co-first authors Correspondence to: Zhiqiang Meng, email: [e-mail] , [e-mail] Keywords: hepatocellular carcinoma, systemic inflammation response index, local therapy, systemic therapy, survival Received: August 01, 2016      Accepted: March 24, 2017      Published: April 05, 2017 ABSTRACT The systemic inflammation response index (SIRI) is a useful tool for predicting prognosis in some types of cancer. In this retrospective study, we evaluated the efficacy of SIRI in predicting overall survival in hepatocellular carcinoma (HCC) patients following local or systemic therapy. A cutoff value of 1.05 was identified for SIRI using ROC analysis in a training patient cohort. In the validation cohort, survival analysis revealed that median overall survival was longer in HCC patients with SIRI scores < 1.05 than in those with scores ≥ 1.05. Cox analysis of the validation cohort demonstrated that SIRI was associated with overall survival and was more predictive of overall survival that the AFP level or Child-Pugh score. However, SIRI and Barcelona Clinic Liver Cancer (BCLC) stage were equally effective for predicting survival. In addition, HCC patients with BCLC stage C had higher SIRI scores and poorer overall survival. SIRI also correlated with liver function parameters. Thus SIRI may be a convenient, low cost and reliable tumor marker for predicting prognosis in HCC patients.